Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $89.90 Average Price Target from Brokerages

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned a consensus recommendation of “Buy” from the thirteen brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $89.90.

Several research firms have commented on JANX. UBS Group started coverage on shares of Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 price objective on shares of Janux Therapeutics in a research report on Wednesday, December 11th. BTIG Research increased their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Lifesci Capital raised Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. Finally, Leerink Partnrs raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, November 22nd.

Insider Transactions at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $51.60, for a total transaction of $1,290,000.00. Following the transaction, the chief executive officer now directly owns 257,054 shares of the company’s stock, valued at approximately $13,263,986.40. The trade was a 8.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $42.29, for a total value of $140,994.86. Following the completion of the transaction, the insider now owns 82,139 shares of the company’s stock, valued at approximately $3,473,658.31. This represents a 3.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 86,668 shares of company stock valued at $4,872,515 over the last 90 days. Corporate insiders own 29.40% of the company’s stock.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors have recently added to or reduced their stakes in JANX. Dimensional Fund Advisors LP increased its position in shares of Janux Therapeutics by 54.0% during the second quarter. Dimensional Fund Advisors LP now owns 24,019 shares of the company’s stock worth $1,005,000 after acquiring an additional 8,422 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Janux Therapeutics during the 2nd quarter worth approximately $215,000. The Manufacturers Life Insurance Company raised its position in shares of Janux Therapeutics by 234.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,048 shares of the company’s stock valued at $1,007,000 after purchasing an additional 16,864 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after buying an additional 339 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in shares of Janux Therapeutics by 639.5% during the third quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company’s stock worth $924,000 after buying an additional 17,592 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX opened at $36.11 on Friday. The company has a 50-day simple moving average of $50.54 and a 200-day simple moving average of $48.23. The company has a market cap of $1.90 billion, a PE ratio of -30.86 and a beta of 3.16. Janux Therapeutics has a 12 month low of $7.81 and a 12 month high of $71.71.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.